Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Cash from Financing Activities for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 5215.38% year-over-year to $1.4 million, compared with a TTM value of $2.1 million through Dec 2025, up 1198.12%, and an annual FY2025 reading of $2.1 million, up 1198.12% over the prior year.
  • Cash from Financing Activities was $1.4 million for Q4 2025 at Treace Medical Concepts, up from -$10000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $107.9 million in Q1 2023 and bottomed at -$1.2 million in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $12.0 million, with a median of $304000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities crashed 3793.94% in 2021, then skyrocketed 7762.9% in 2023.
  • Year by year, Cash from Financing Activities stood at $1.0 million in 2021, then tumbled by 71.05% to $297000.0 in 2022, then plummeted by 44.44% to $165000.0 in 2023, then tumbled by 84.24% to $26000.0 in 2024, then skyrocketed by 5215.38% to $1.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TMCI at $1.4 million in Q4 2025, -$10000.0 in Q3 2025, and $987000.0 in Q2 2025.